|Bid||32.31 x 1300|
|Ask||39.95 x 4000|
|Day's Range||31.58 - 34.75|
|52 Week Range||24.54 - 39.44|
|Beta (3Y Monthly)||0.96|
|PE Ratio (TTM)||89.84|
|Earnings Date||Jan 30, 2019 - Feb 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||42.30|
Stocks that moved substantially or traded heavily Tuesday: Target Corp., down $8.12 to $69.03 The retailer's profit fell short of Wall Street expectations as it invested more in its stores and its online ...
Moody's Investors Service ("Moody's") today affirmed Boston Scientific Corporation's Baa2 senior unsecured ratings and its Prime-2 commercial paper rating. The affirmation of the ratings follows Boston Scientific's announcement that it has reached an agreement to acquire BTG Plc, a UK-based medical products company. Under the terms of the offer, Boston Scientific will acquire BTG for approximately GBP 3.3 billion ($4.2 billion at current exchange rates).
US medical device maker Boston Scientific is backing its recommended cash offer for UK-based BTG plc with a £3.3bn bridge loan from Barclays Bank. The bridge loan covers the full amount of the cash consideration and satisfies the certain funds requirements of the UK Takeover Code. The acquisition, which has been unanimously approved by the boards of directors of Boston Scientific and BTG, is expected to be carried out through an English court-sanctioned scheme of arrangement, and is expected to close in the first half of 2019.
Boston Scientific Corp. on Tuesday agreed to buy British healthcare company BTG plc in a $4.2 billion deal. The Marlborough, Mass.-based medical device maker offered $10.77 for each BTG share, representing a premium of 36.
While the deal will give Boston Scientific new products for the treatment of cancer and other disorders, it will add to the U.S. company’s debt. Boston Scientific “has takeout speculation in shares and thus doing a deal will be a perceived negative as far as the stock is concerned,” Holz said in a note to clients. Boston Scientific, a maker of stents that hold open damaged blood vessels, will pay 840 pence in cash per share, a 37 percent premium over BTG’s Monday closing price, according to a statement.
One of the state's biggest medical device companies is getting even bigger through a global acquisition.
Boston offered 840p in cash for BTG, a premium of 36.6 per cent to its Monday closing price. Analysts saw a counterbid as unlikely given what Jefferies called BTG’s “somewhat eclectic product mix” and the competition risks facing CroFab, its top-selling rattlesnake antivenom. Panmure Gordon called the price “fair, though not generous” at 15.2 times 2019 earnings, against the sector average for takeovers of 24 times earnings.
Check out the companies making headlines before the bell: Target TGT – The retailer earned an adjusted $1.09 per share for the third quarter , 3 cents a share below estimates. Revenue exceeded forecasts, however, and comparable-store sales were up 5.
General Electric’s (GE) Healthcare segment, which offers medical imaging and information technologies, biopharmaceutical manufacturing technologies, and patient monitoring systems, is one of the company’s better-performing units and is the fourth-largest contributor to its total revenue.
U.S. medical device maker Boston Scientific Corp (BSX.N) has agreed to buy Britain's BTG Plc (BTG.L) for 3.3 billion pounds in cash, adding technology to fight cancer and other serious diseases to its portfolio. Boston Scientific - best known for making stents to prop open clogged heart arteries - has agreed to pay 840 pence per share, representing a premium of 36.6 percent to BTG's previous closing price, the companies said on Tuesday. Shares of BTG soared by a third to 825p by 1200 GMT after touching 832p, their highest level since Jan. 2015.
U.S. medical device maker Boston Scientific Corp has agreed to buy Britain's BTG Plc for 3.3 billion pounds ($4.24 billion) in cash, adding technology to fight cancer and other serious diseases to its portfolio. Boston Scientific - best known for making stents to prop open clogged heart arteries - has agreed to pay 840 pence per share, representing a premium of 36.6 percent to BTG's previous closing price, the companies said on Tuesday. Shares of BTG soared by a third to 825p by 1200 GMT after touching 832p, their highest level since Jan. 2015.
Boston Scientific Corp. has seen its chance and agreed to buy London-based BTG Plc for 3.3 billion pounds ($4.2 billion). If the deal is consummated, the British maker of medical devices will join the growing list of internationally-flavored U.K. companies falling prey to overseas bidders. This has been a rough year for BTG.
Corp. on Tuesday said it had agreed to buy British health-care firm BTG PLC for £3.3 billion ($4.24 billion), bolstering its presence in the growing field of interventional medicine. The Marlborough, Mass.-based medical devices maker said it would pay 840 pence a share in cash for BTG, a 37% premium to the U.K.-listed company’s closing price Monday. BTG’s shares jumped 33% on the news.
U.S. listed tech stocks extended their slump in pre-market trading Tuesday, with Apple looking to slide into bear market territory, as investors continue to dump the so-called FAANG stocks amid persistent concerns over consumer demand, U.S.-China trade talks and rising interest rates. Apple shares were marked 1.4% lower in pre-market trading Tuesday, indicating an opening bell price of $183.25 each, a move that would take the decline since its October 3 close past 20% Nvidia shares, which have fallen more than 27% over the past week alone, are indicated to slide another 2.8% to 140.60 each. , which has fallen nearly 40% since late July amid a host of data privacy, corporate governance and profitability concerns, was marked 1.2% lower in pre-market trading, indicating an opening bell price of $130 each.
Boston Scientific has agreed a takeover bid for U.K. specialty health-care company BTG in a deal worth £3.3 billion.
Boston Scientific said Tuesday that it has agreed to a takeover bid for U.K. specialty health-care company BTG in a deal worth 3.3 billion pounds ($4.23 billion).
U.S. medical device maker Boston Scientific Corp said it offered to buy British pharmaceutical firm BTG Plc for about 3.3 billion pounds ($4.24 billion) in cash. The offer of 840 pence in cash per share represents a premium of 36.6 percent to BTG's close of 615 pence on Monday. BTG said it plans to recommend the deal to its shareholders as it considers the terms to be fair and reasonable.
The transaction has been unanimously approved by the boards of directors of Boston Scientific and BTG. Under the terms of the transaction, holders of BTG's common shares would receive cash consideration of 840 pence per share. The total cash consideration for 100% of BTG's equity is approximately £3.3B, or U.S.$4.2B.
, were spiking 36 per cent on Tuesday morning — partly because it makes a snakebite cure. At 840p a share, this was 37 per cent higher than BTG’s closing price on Monday, and 51 per cent above its weighted average share price over the past three months.
The deal will see Boston Scientific pick up the jumble of healthcare products owned by BTG, which has spent the past few years reducing its reliance on an expensive rattlesnake bite antidote that faces increased competition. It also comes after executive pay criticism against Dame Louise Makin, BTG’s chief executive, over future stock awards and bonus arrangements put in place for the company’s former finance director. Last month, BTG chairman Garry Watts announced his intention to retire by the end of the year.
In November, among the 17 analysts covering Baxter International (BAX), ten analysts recommended a “buy” or a higher rating, five recommended a “hold” rating, and three recommended a “sell” rating. The mean rating for Baxter International stock is 2.29 with a target price of $73.27, which implies an upside potential of 11.3% over Baxter International’s closing price of $65.83 on November 15.
Baxter International’s (BAX) cost of sales decreased from $1.58 billion in the third quarter of 2017 to $1.53 billion in the third quarter. The company’s gross profit increased from $1.13 billion in the third quarter of 2017 to $1.24 billion in the third quarter due to the favorable product mix and manufacturing efficiencies.
Fluctuations in Baxter International’s (BAX) stock price have kept investors interested in the stock in 2018. In this series, we’ll discuss Baxter International’s financials, analysts’ views on the stock, valuation metrics, and geographic performance. The company’s business units include renal care, medication delivery, pharmaceuticals, clinical nutrition, advanced surgery, and acute therapies.
Marlborough-based Boston Scientific will make changes to its supply chain network and anticipates some layoffs over the next few years, according to a federal filing on Thursday.